Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Bill Woywod
Advertisement
Articles by Bill Woywod
How machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.
Advertisement
Latest Updated Articles
How Machine Learning Gives Life Sciences Sales a Competitive AdvantageNovember 22nd 2019
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Wegovy HD Injectable Under Accelerated Approval
2
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
3
What Are the ‘Last Mile Issues’ Impacting Pharma?
4
Pharmaceutical Executive Daily: FDA Approves Wegovy HD
5